Stay updated with breaking news from Mutation Testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WILMINGTON, Del.--(BUSINESS WIRE)--Jun 2, 2024--
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients —
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If...
First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting ...
AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit.